Cholestyramine Light

Bile acid sequestering agent that decreases absorption of CHENODIOL in the intestine, resulting in decreased efficacy. Concomitant use should be avoided.

Reduces amiodarone serum levels.

Hyperkalemic metabolic acidosis has been reported with concomitant use of CAROSPIR and cholestyramine.

May increase the clearance of dexamethasone and potentially decrease corticosteroid exposure. Avoid coadministration and consider alternative agents.

Cholestyramine may delay or reduce digitalis absorption; discontinuance poses hazard if digitalis was titrated to maintenance level during cholestyramine use.

Absorption of hydrochlorothiazide is impaired; single doses reduce absorption by up to 85%.

Cholestyramine binds thyroid hormones in the intestine, impairing their absorption. Space administration by 4-5 hours.

May decrease mycophenolic acid concentrations through interference with enterohepatic recirculation; concomitant use is not recommended.

Cholestyramine decreases MPA AUC by approximately 40%. Not recommended for concomitant use due to interruption of enterohepatic recirculation.

Reduces the absorption and enterohepatic cycling of raloxifene. Use with raloxifene hydrochloride tablets is not recommended.

Reduces absorption and enterohepatic cycling of raloxifene by 60%. Concomitant use is not recommended.

Hyperkalemic metabolic acidosis has been reported with concomitant use of spironolactone and cholestyramine.

Hyperkalemic metabolic acidosis has been reported with concurrent use.

Cholestyramine may delay or reduce the absorption of warfarin. Discontinuance could pose a hazard if warfarin has been titrated to maintenance level.

Bile acid sequestrant that may impair the absorption of cholecalciferol. Additional vitamin D supplementation should be considered.

Absorption of hydrochlorothiazide is impaired; single doses bind hydrochlorothiazide and reduce its absorption by up to 85 percent.

Cholestyramine may delay or reduce the absorption of thiazide diuretics (acidic).

Concomitant use decreases ezetimibe concentration, potentially reducing efficacy. Administer NEXLIZET at least 2 hours before or 4 hours after cholestyramine.

May increase the clearance of corticosteroids.

May impair absorption of calcifediol. Dose adjustment and monitoring of serum 25-hydroxyvitamin D, PTH, and calcium may be required.

May impair intestinal absorption of calcitriol by reducing absorption of fat-soluble vitamins.

May reduce intestinal absorption of calcitriol by impairing fat-soluble vitamin absorption.

Binds hydrochlorothiazide and reduces its absorption by up to 85%. Stagger dosing appropriately.

Cholestyramine may bind thiazide diuretics and reduce diuretic absorption from the gastrointestinal tract.

Bile acid binding resin that adsorbs and reduces bile acid absorption, potentially reducing CHOLBAM efficacy. Take CHOLBAM at least 1 hour before or 4-6 hours after.

Cholestyramine may increase the clearance of oral corticosteroids.

Cholestyramine may increase the clearance of dexamethasone.

Cholestyramine may increase the clearance of dexamethasone.

Decreases digoxin concentrations. Requires monitoring and dose adjustment.

Reduces intestinal absorption of fat-soluble vitamins including doxercalciferol. Administer doxercalciferol at least 1 hour before or 4-6 hours after cholestyramine.

Cholestyramine may interfere with biliary excretion of entacapone; caution should be exercised when used concurrently.

Cholestyramine may delay or reduce the absorption of estrogens.

Cholestyramine decreases mean exposure of total ezetimibe, resulting in reduced efficacy. Administer ezetimibe at least 2 hours before or 4 hours after cholestyramine.

Combination decreases exposure of ezetimibe, reducing efficacy.

Cholestyramine impairs gastrointestinal folate uptake through binding of dietary folate.

Cholestyramine may increase the clearance of corticosteroids, reducing corticosteroid effects.

Cholestyramine may increase the clearance of corticosteroids, reducing corticosteroid effects.

Reduced absorption of thiazides when coadministered with cholestyramine.

Cholestyramine may increase the clearance of corticosteroids.

Cholestyramine may delay or reduce the absorption of thyroxine preparations.

Bile acid sequestrant known to decrease levothyroxine absorption, potentially resulting in hypothyroidism.

Bile acid sequestrant that may decrease T3 absorption by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Administer liothyronine sodium at least 4 hours prior.

Reduced absorption of thiazides. Monitor therapeutic effect of hydrochlorothiazide.

Bile acid binding resin may bind to maralixibat in the gut. Administer LIVMARLI at least 4 hours before or after cholestyramine.

Cholestyramine may increase the clearance of corticosteroids.

Cholestyramine may increase the clearance of corticosteroids, reducing their effectiveness.

Cholestyramine may increase the clearance of corticosteroids.

Cholestyramine may increase the clearance of oral corticosteroids.

Cholestyramine may increase the clearance of corticosteroids, reducing their effectiveness.

Ion exchange resin that reduces hydrochlorothiazide absorption by up to 85%. Stagger dosing with at least 4 hours separation.

Bile acid sequestrant that interferes with enterohepatic recirculation, decreasing mycophenolic acid systemic exposure and potentially reducing Mycophenolate Mofetil efficacy.

Concomitant administration can delay the absorption of naproxen.

Bile acid binding resins may bind odevixibat in the gut, reducing BYLVAY efficacy. Administer at least 4 hours before or after odevixibat.

Reduces absorption of hydrochlorothiazide, decreasing its therapeutic effect.

Reduces absorption of hydrochlorothiazide.

Reduces absorption of thiazides.

Reduces absorption of thiazides. Monitor for reduced diuretic efficacy.

Impairs intestinal absorption of fat-soluble vitamins and may reduce paricalcitol absorption. Separate dosing by at least 1 hour before or 4-6 hours after.

Cholestyramine may delay or reduce the absorption of penicillin G.

Cholestyramine may delay or reduce the absorption of phenobarbital.

Cholestyramine may delay or reduce the absorption of phenylbutazone.

Cholestyramine interferes with absorption of oral phosphate supplements.

Concomitant administration decreases pravastatin AUC by 40-50%; clinically significant timing separation required.

Cholestyramine may increase the clearance of corticosteroids.

Cholestyramine may increase the clearance of corticosteroids, potentially reducing prednisone effectiveness.

Reduces folic acid absorption and reduces serum folate levels.

Cholestyramine may delay or reduce the absorption of propranolol (basic).

Co-administered cholestyramine significantly reduces propranolol plasma concentrations, resulting in loss of efficacy.

Cholestyramine reduces absorption of thiazides, potentially decreasing their efficacy.

Cholestyramine may delay or reduce the absorption of tetracycline.

Cholestyramine may delay or reduce the absorption of thyroid preparations.

Cholestyramine may delay or reduce the absorption of thyroid preparations.

Binds levothyroxine (T4) and liothyronine (T3) in the intestine, impairing absorption of thyroid hormones. Separate administration by 4-5 hours.

Decreases absorption and exposure of orally administered torsemide. Administer torsemide at least 1 hour before or 4-6 hours after cholestyramine.

Cholestyramine may increase the clearance of corticosteroids, reducing their effect.

Cholestyramine may increase the clearance of corticosteroids.

Bile acid sequestering agent that may interfere with ursodiol action by reducing its absorption.

Bile acid sequestering agent may interfere with ursodiol absorption and reduce its effectiveness.

Bile acid sequestering agent that may interfere with ursodiol action by reducing its absorption.

Decreases plasma levels of valproic acid by approximately 14%. Delaying cholestyramine administration by 3 hours may lessen the interaction.

Ion exchange resin may interact with hydrochlorothiazide; dosage staggering is recommended.

Administration of cholestyramine does not affect the relative bioavailability of dutasteride.

Drug Interactions Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins and digitalis.